Background and objective: Idiopathic pulmonary fibrosis (IPF) has a poor prognosis in general; however, it is heterogeneous to detect relative biomarkers for predicting the disease progression. Serum biomarkers can be conveniently collected to detect and help to differentially diagnose IPF and predict IPF prognosis. This meta-analysis aimed to evaluate the use of serum surfactant proteins A and D (SP-A and SP-D) for differential diagnosis and prognosis of IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease (ILD) of unknown etiology. [1] Several studies have indicated that the worldwide incidence of IPF seems to be increasing, especially in Europe and North America. [2] IPF is histologically characterized by the usual interstitial pneumonia (UIP) pattern. True UIP patterns are also found in rheumatoid lung, asbestosis, and, rarely, in sarcoidosis. [3] The primary diagnostic method of IPF in current clinical practice is the high-resolution computed tomography (HRCT), lung biopsy. [4] Incorporating with noninvasive biomarkers (eg, matrix metalloproteinase-7 [MMP7], surfactant protein-D [SP-D]) would provide additional evidence for HRCT and clinical history when distinguish IPF from other ILDs, and they may have the ability to predict risk for acute exacerbation (AE) of IPF patients. [5] The median survival of patients with IPF is 3 years and the 5-year survival rate is 20% to 40%. [6, 7] Pathologist features, [8] clinical parameters, [9, 10] and prediction models, [11, 12] including lung function test, the 6-minute walk test, and the clinical, radiological, and physiological (CRP) scoring system, have been used as prognostic tools. However, since the clinical course of individual patients is highly variable and unpredictable, these physiologic parameters have limitations. [13] Alternatively, noninvasive biomarkers may be helpful in identifying patients with IPF and predicting long-term outcome.
Type II counterproductive molecules, Krebs von den Lungen-6 (KL-6), surfactant protein-A (SP-A), SP-D, MMP-7, and CCcheekiness Gilligan 18 (CCL18) have emerged as potential diagnostic and prognostic biomarkers of IPF. [14] SP-A and SP-D are hydrophobic, collagen-containing calcium-dependent lectins, with a range of nonspecific immune functions at pulmonary and cardiopulmonary sites. [15] SP-A and SP-D play crucial roles in the pulmonary immune response, and are secreted by type II pneumocytes, nonciliated bronchiolar cells, submucosal glands, and epithelial cells of other respiratory tissues, including the trachea and bronchi. SP-D is important in maintaining pulmonary surface tension, and is involved in the organization, stability, and metabolism of lung parenchyma. [16] Serum SP-A and SP-D have been identified as biomarkers for pulmonary diseases, including acute respiratory distress syndrome (ARDS), [17] chronic obstructive pulmonary disease (COPD), [18] and progressive systemic sclerosis (PSS). [19] Previous studies had reported that serum SP-A and/or SP-D were significantly different from IPF and some non-IPF ILD patients (eg, rheumatoid arthritis-associated ILD). [5] Meanwhile, SP-A and SP-D levels in BALF may also play a role in differential diagnosis from IPF and other ILDs (eg, sarcoidosis) [20] and predicting survival in IPF patients. [21] In IPF patients, serum SP-A or SP-D also plays helpful roles in differential diagnosis [22] as well as predicting prognosis. [14] Before this study, the potential role of serum SP-A and SP-D as diagnostic and prognostic biomarkers in patients with IPF had not been studied by meta-analysis. The goal of this study was to evaluate the role of SP-A and SP-D in the diagnosis and prognosis of IPF.
Materials and methods

Search strategy and ethics permission
In March 2017, we performed systematic searches in PubMed, EMBASE, and the Chinese National Knowledge Infrastructure (CNKI). We used the following search terms: "Surfactant protein" or "SP" and "Idiopathic pulmonary fibrosis" or "IPF" or "Interstitial lung disease" or "Pulmonary fibrosis." We also identified relevant publications by reviewing the reference of the search results. The meta-analysis was approved by the Ethics Committee of the Xijing Hospital, the First Affliated Hospital of the Fourth Military Medical University.
Inclusion and exclusion criteria
Included studies met the following criteria: SP-A and/or SP-D were evaluated in human subjects for the differential diagnosis and prognosis of IPF. In comparison part, patients with IPF were compared to at least one reference group (non-IPF patients or healthy subjects). Studies were written in English or Chinese. A definitive diagnosis of IPF was evident by clinical features, chest HRCT, laboratory findings, and/or surgical lung biopsy. Data, for example, serum levels of SP-A and SP-D, and hazard ratios (HRs), were available from the reviewed articles. In addition, for inclusion in the prognostic evaluation of SP-A/SP-D in patients with IPF, studies had to have a defined patient follow-up schedule, and include death as an endpoint. Studies were excluded if the data were unavailable after attempts to contact author.
Data extraction and quality assessment
Two reviewers independently screened titles and abstracts for potentially eligible articles. Full texts of articles were obtained, and 2 reviewers independently determined eligibility. Discrepancies were resolved by a discussion or with a third reviewer. For every eligible study, we extracted the following information: first author, year of publication, number and sex of patients with IPF, patient smoking history, study endpoints, study methods, and epidemiological study methods. When the association between SP-A/SP-D and IPF mortality was studied, cutoff values for SP-A and SP-D were also collected. When study data for meta-analysis were not available in the article, we attempted to contact author (s) to obtain original data. Some original data were not available. In this case, we derived mean and standard deviation using median and range from graphs and curve diagrams, according to the method recommended by Hozo et al. [23] In one case, the relative risk of mortality data was presented as Kaplan-Meier curves, not HR and 95% confidence interval (CI). [24] In this case, we calculated the HR and 95% CI according to the method described by Parmar et al. [25] In the analysis of the association of SP-A/SP-D with death of patients with IPF, there was an overlap of subjects in the studies of Greene et al. [26] and Kinder et al. [27] . To avoid sampling bias, we included only the Greene et al.'s [26] study in the analysis.
We used Newcastle-Ottawa quality assessment scale of case control studies to evaluate the quality of these studies. [28] A study could be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of 2 stars could be given for comparability. A study with >5 stars was included in the meta-analysis.
Statistical analysis
Statistical analyses were conducted using STATA software (Stata Corp, TX, version 12.0). All tests were 2-tailed with the significance level set at P < .05. For analyses of SP-A/SP-D as diagnostic and prognostic biomarkers, Cochran's Q test was used to assess between-study heterogeneity. Heterogeneity was 96: 23 Medicine presented in the form of the inconsistency index, I 2 , ranging from 0% to 100%. [29] To assess heterogeneity, the value of I 2 was divided into 3 groups: <25%, 25% to 75%, and >75%, corresponding to low, moderate, and high heterogeneity. If statistical heterogeneity existed, the potential causes were estimated using sensitivity and subgroup analysis. A randomeffect model was applied to reduce the effect of heterogeneity. To estimate the potential publication bias, we used a funnel plot and Egger's test. An asymmetric funnel plot and a P < .05 on the Egger's test identified the existence of publication bias.
When assessing the diagnostic effect of SP-A/SP-D, we treated the biomarkers as continuous, and gave an estimate of the combined overall effect size utilizing standard mean difference (SMD) in the random-effects model. For the evaluation of SP-A/ SP-D as prognostic biomarkers of mortality, we used the Z test to test the pooled HR, and presented both a Z and P value. We compared the weight of the individual article in influencing the pooled HR, and the 95% CI. We also did subgroups analysis, stratified by race, for both diagnostic and prognostic analysis.
Results
Study inclusion, characteristics, and study quality
We identified articles from three databases: PubMed (n = 1353), EMBASE (n = 1230), and CNKI (n = 305). Nine hundred and ninety duplicate articles were removed. We excluded 1877 articles that failed to meet the inclusion criteria. A final group of 21 articles met the eligibility criteria [5, 14, 22, 24, 26, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] (Fig. 1 ). Seven of 21 articles evaluated the prognosis of IPF as an outcome and the observed endpoint was death (Table 1) . Eighteen studies compared the serum level of SP-A/SP-D in patients with IPF to patients with non-IPF ILD or pulmonary infection, or healthy controls. All 21 articles were retrospective studies, and none of these studies reported blindness. No relevant prospective studies or large-scale meta-analyses were identified. The main characteristics of the 21 articles are summarized in Table 1 . A total of 1289 patients with IPF were included for analyses. The majority of patients (>58%) were Asian. The date of publication ranged from 1992 to 2016. Data reflecting severity included FEV 1 % predicted, FVC% predicted, and DLco% predicted. DLco% predicted values varied from 39.1% to 74.9%. The number of male patients was greater than the number of female patients.
According to study quality assessment criteria (Supplemental Table 1 , http://links.lww.com/MD/B723), the study participation was adequate and the baseline study sample was completely delineated in all included articles. Every study that assessed the prognostic effect of SP-A/SP-D included patient follow-up. All studies assessed SP-A and (or) SP-D levels; however, different cutoff values were used, as described in Table 1 www.md-journal.com Table 1 Baseline information for all articles included. Moreover, 5-year survival rates based on these cutoff points were listed in Supplemental Supplemental Fig 1, http: //links.lww.com/MD/B724). These comparisons suggest a high level of heterogeneity (I 2 = 95.8%, 87.0%, respectively, with P < .001, Supplemental Fig 1, http://links.lww.com/MD/B724). To further evaluate the cause of heterogeneity, we repeated the serum SP-A level comparisons in specific diseases. The SP-A levels were significantly higher in patients with IPF than in patients with sarcoidosis and pneumonia, but not collagen vascular disease-associated interstitial pneumonia (SMD: 0.344 [À0.158, 0.846], Z value = 1.34, P = .180; Table 2 ).
Serum SP-D levels in patients with IPF were significantly higher than SP-D in patients with pulmonary infection (SMD: 1.308 [0.813, 1.803], Z value = 5.18, P < .001; Fig. 3 Table 2 ). Only Kakugawa's research reported elevated SP-A and potentially elevated SP-D level in AE phase compared to stable phase in the same patients. [35] 3.2.2. Prognostic analysis. Seven publications were included to evaluate the effect of serum levels of SP-A and SP-D on the death of patients with IPF. A higher SP-A level was associated with a significantly higher risk of death, and there was no heterogeneity (pooled HR: 1.39 [1.10, 1.75], Z value = 2.80, P = .005, I 2 = 0.0%; Fig. 4A ). There was a significant association between higher SP-D level and increased risk of death, without heterogeneity (HR: 2.11 [1.60, 2.78], Z value = 5.31, P < .001, I 2 = 0.0%; Fig. 4B ). Sensitivity analysis indicated that no specific study influenced the pooled HR (Supplemental Fig. 3 , http://links. lww.com/MD/B724).
No obvious asymmetry was observed in the funnel plot regarding the association between SP-A and death (Egger's test: P = .388; Fig. 4C ), indicating no evidence of publication bias.
Similar asymmetry was observed for the association between SP-D and death (Egger's test: P = .276; Fig. 4D ). 3 .252], P < .001) was a risk factor for increased mortality, while a higher SP-A was not associated with increased mortality (pooled HR 1.459, 95% CI [0.740, 2.879], P = .276).
Race subgroup analysis
Discussion
In this study, serum levels of SP-A could be used to differentiate patients with IPF from patients with non-IPF ILD, pulmonary Different cutoff points may due to different calculation methods, race, severity, and so on. Higher SP-A and SP-D serum levels among patients with IPF may be a result of genetic and environmental susceptibility. Pulmonary fibrosis may occur in genetically susceptible individuals after exposure to one of several environmental stressors. These stressors cause abnormal surfactant synthesis, secretion, and recycling, in both children and adults. [46] Serum levels of SP-A and SP-D are significantly elevated in patients with IPF, bacterial pneumonia, and tuberculosis, compared to the healthy controls. Kati et al. [47] suggested that serum SP-D levels were significantly higher in patients with IPF and submassive pulmonary embolism than in controls and SP-D may have a diagnostic role in sub-massive pulmonary embolism.
AE of IPF is characterized by an acute worsening of dyspnea, with the potential of hypoxemic respiratory failure, and new or progressive pulmonary infiltrates on radiologic images. [48] There is a difference in levels of serum SP-A and SP-D between stable and AE of IPF. In this study, we found that serum levels of SP-A and SP-D increased significantly in an AE of IPF, when compared to levels in stable IPF. Pathologically, it may result from functional abnormalities of type II alveolar epithelial cells, including endothelial cells injuries and coagulation abnormalities. [49] Therefore, SP-A and SP-D, reflecting type II alveolar epithelial cell injury and proliferation, will increase with an AE of IPF. However, in clinical practice, the combination of serum SP-A/SP-D with other predictors (eg, symptoms or HRCT) will enhance diagnostic accuracy of AE.
Elevated SP-A and SP-D in patients with IPF is likely the result of increased secretion by type II alveolar epithelial cells. An increase in total number of type II cells, resulting from diffuse hyperplasia, leads to increased leakage from the alveoli to the interstitium, and decreased clearance from vascular compartment. Selman and Pardo [50] reported that IPF was not an inflammatory disorder, and that alveolar epithelial cell damage and activation were a result of constant microscopic injury. Hyperplasia of type II alveolar epithelial cells results in loss of type I alveolar epithelial cells. In patients with IPF, Nishikiori et al. [20] identified thickened matrix, near the alveolar space, and capillary hyperplasia was detected using CD34. [51, 52] These capillaries were near the regenerated type II alveolar epithelial cells, and were SP-A and SP-D positive. Surfactant proteins can leak directly into the bloodstream through capillaries instead of lymphatic ducts.
The blood-air barrier of lung comprises the alveolar epithelium, alveolar epithelial basal layer, substantia propria, capillary basement membrane, and capillary endothelial cells. Injury to any part of the barrier will increase permeability, resulting in leakage of SP-A and SP-D from the alveolus to the capillaries. Barbas-Filho et al. [53] conducted a retrospective study including 55 patients with histologically confirmed IPF. Using electron microscopy, they detected apoptosis in 89% of the patients with IPF/UIP.
In animal experiments, alveolar epithelial cell death was observed, and bleomycin was used to induce pulmonary fibrosis. [54, 55] Repeated injuries of alveolar epithelial cells resulted in cell death, but the exact mechanism is unclear. Angiotensin II and Fas signaling were associated with alveolar epithelial cell death in bleomycin-induced lung injury. [56, 57] The inflammatory reaction may be involved in the pathogenesis of IPF. There is evidence of immune cell infiltration and inflammatory cytokine production in patients with IPF. Carre et al. [58] reported that the levels of interleukin-8 (IL-8) mRNA in alveolar macrophages, and the level of IL-8 protein in bronchoalveolar lavage, were significantly higher in patients with IPF than in healthy subjects. Both IL-8 mRNA and IL-8 protein were associated with disease severity. Other cytokines and chemokines, including tumor necrosis factor alpha (TNF-a), IL-1b, IL-4, and IL-5, are overexpressed in patients with IPF. [59, 60] In an inflammatory environment, capillary permeability increases, and SP-A and SP-D leakage from the alveolus to the capillary increases. Mechanisms include damage of the junction of capillary endothelial cells, dysfunction of endothelial cell signal transduction, and release of inflammatory cytokines.
In addition, the concentration difference between alveolar airspace and the blood and reduction of SP clearance contribute to the elevation of the serum levels of SP-A and SP-D. IPF and non-IPF ILD have a similar pathogenesis. We found no significant differences in the serum concentration of SP-A and SP-D between patients with IPF and non-IPF ILD (including progressive systemic sclerosis, pulmonary alveolar proteinosis, idiopathic The median survival of patients with IPF patients is three years, indicating a poor prognosis. [61] Despite the potential use of SP-A/ SP-D as diagnostic aids, the diagnosis of IPF is confirmed by surgical biopsy or HRCT. According to guidelines, serum SP-A/ SP-D cannot replace biopsy or HRCT. [4] However, SP-A/SP-D has the following advantages. First, SP-A/SP-D serum levels could be preliminarily evaluated in patients apprehensive of traumatic examination and surgery. Second, image findings in HRCT are not typical, which complicate the diagnosis, and may delay early diagnosis and treatment. Other physiological measurements have been suggested for predicting the severity and prognosis of patients with IPF, including the GAP index [62] (gender, age, and 2 lung physiology variables, FVC and DLco) and the CPI [13] (composite physiologic index). Ley et al. [62] reported that the GAP index and staging system and the GAP calculator were better predictors of morality in patients with IPF than previously developed prediction models. This method has important utility for both clinical practice and trials. Our analyses indicate that the use of serum biomarkers should not replace the existing physiological measurements for predicting prognosis, as each method has its own limitation. Combining these methods (eg, GAP models, HRCT, and serum biomarkers) could increase the accuracy and sensitivity in determining the prognosis of patients with IPF. Several studies suggested that serum SP-A and/or SP-D can combine with existing physiologic parameters to enhance the ability of predicting survival. Those clinical variables include age, smoking status, FVC, Dlco, and so on. [27, 44] Our study still has several limitations. Although we tried to control the study quality by the Newcastle-Ottawa quality assessment scale, the included studies were all retrospective, which intrinsically presents difficulty in causality inference. Only Chinese and English articles were included in this analysis. Statistical heterogeneity was prevalent among our included studies in the overall analyses. The cutoff of high versus low serum levels was inconsistent among the included publications. In the articles included, 3 did not provide a specific cutoff value, and we were unable to obtain the original data. Among the cutoff values provided by the author, the numbers in each article were different.
